4.6 Article

The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth

Journal

CANCERS
Volume 12, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/cancers12061464

Keywords

Burkitt lymphoma; miR-26b-5p; microRNA; KPNA2

Categories

Funding

  1. China Scholarship Council (CSC)
  2. University Medical Center of Groningen [601317]
  3. Cock-Hadders foundation
  4. National Science Centre, Poland [2016/23/D/NZ1/01611]

Ask authors/readers for more resources

The expression of several microRNAs (miRNAs) is known to be changed in Burkitt lymphoma (BL), compared to its normal counterparts. Although for some miRNAs, a role in BL was demonstrated, for most of them, their function is unclear. In this study, we aimed to identify miRNAs that control BL cell growth. Two BL cell lines were infected with lentiviral pools containing either 58 miRNA inhibitors or 44 miRNA overexpression constructs. Eighteen constructs showed significant changes in abundance over time, indicating that they affected BL growth. The screening results were validated by individual green fluorescent protein (GFP) growth competition assays for fifteen of the eighteen constructs. For functional follow-up studies, we focused on miR-26b-5p, whose overexpression inhibited BL cell growth. Argonaute 2 RNA immunoprecipitation (Ago2-IP) in two BL cell lines revealed 47 potential target genes of miR-26b-5p. Overlapping the list of putative targets with genes showing a growth repression phenotype in a genome-wide CRISPR/Cas9 knockout screen, revealed eight genes. The top-5 candidates included EZH2, COPS2, KPNA2, MRPL15, and NOL12. EZH2 is a known target of miR-26b-5p, with oncogenic properties in BL. The relevance of the latter four targets was confirmed using sgRNAs targeting these genes in individual GFP growth competition assays. Luciferase reporter assay confirmed binding of miR-26b-5p to the predicted target site for KPNA2, but not to the other genes. In summary, we identified 18 miRNAs that affected BL cell growth in a loss- or gain-of-function screening. A tumor suppressor role was confirmed for miR-26b-5p, and this effect could at least in part be attributed to KPNA2, a known regulator of OCT4, c-jun, and MYC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Hematology

Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma

Gerben Duns, Melanie Winkle, Lauren Chong, Daisuke Ennishi, Ryan D. D. Morin, Arjan Diepstra, David W. W. Scott, Joost L. L. Kluiver, Christian Steidl, Anke van den Berg

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Bibliography Oncology

Obituary-Pieter Van Vlierberghe (1980-2022)

Malgorzata Dawidowska, Agnieszka Dzikiewicz-Krawczyk, Natalia Rozwadowska, Panagiotis Ntziachristos, Joost Kluiver, Anke van den Berg, Reiner Siebert, Maciej Giefing

LEUKEMIA (2023)

Article Biochemistry & Molecular Biology

TransCRISPR-sgRNA design tool for CRISPR/Cas9 experiments targeting specific sequence motifs

Tomasz Wozniak, Weronika Sura, Marta Kazimierska, Marta Elzbieta Kasprzyk, Marta Podralska, Agnieszka Dzikiewicz-Krawczyk

Summary: In this study, we developed an online tool called transCRISPR for searching sequence motifs and designing sgRNAs in user-provided genomic regions. The tool provides user-friendly tables and visualizations summarizing the features of identified motifs and designed sgRNAs. Experimental validation showed that sgRNAs designed by transCRISPR efficiently disrupted MYC binding sites and affected the expression of MYC-regulated genes.

NUCLEIC ACIDS RESEARCH (2023)

Review Oncology

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

Fenneke Zwierenga, Bianca A. M. H. van Veggel, Anke Van den Berg, Harry J. M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E. F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. Van der Wekken

Summary: This article provides a comprehensive assessment of drug sensitivity in vitro and in clinical settings for EGFRex20+ mutations in NSCLC. The activating A763_Y764insFQEA mutation shows better tumor response compared to mutations in other regions, suggesting the need for different treatment approaches. Classification beyond exon-based categories is necessary due to marked differences in treatment responses among EGFRex20+ mutations.

CANCER TREATMENT REVIEWS (2023)

Article Biotechnology & Applied Microbiology

Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells

Marta Kazimierska, Aleksandra Lesniewska, Anja Bakker, Arjan Diepstra, Marta Elzbieta Kasprzyk, Marta Podralska, Karolina Rassek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk

Summary: This study found that GCLC plays an important role in Burkitt lymphoma, and inhibiting GCLC can decrease the viability of BL cells. Buthionine sulfoximine has a growth-inhibiting effect on BL cells and can enhance the cytotoxicity of doxorubicin and cyclophosphamide.

JOURNAL OF APPLIED GENETICS (2023)

Letter Oncology

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke Van den Berg, Marcel Nijland

Summary: The study investigates the use of cfDNA for genomic profiling of PTLD, and explores its potential as a screening tool. Analysis showed that 41% of patients had EBV-positive tumors and 76% had stage IV disease. The study provides important insights into the genetic variations and EBV infection in PTLD.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Correction Oncology

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (vol 36, pg 2835, 2023)

Sonja I. Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V. Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, Arjan Diepstra, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni, Attilio Gabbas, Herve Ghesquieres, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Herve Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van den Berg, David J. Van den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager, Nathaniel Rothman

LEUKEMIA (2023)

Article Oncology

CRISPR/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells

Marta Kazimierska, Marta Podralska, Magdalena Zurawek, Tomasz Wozniak, Marta Elzbieta Kasprzyk, Weronika Sura, Wojciech Losiewski, Iwona Ziolkowska-Suchanek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk

Summary: The transcription factor MYC plays a crucial role in the development and maintenance of various types of cancer by binding to specific E-box sequences in the genome to regulate gene expression. Through the use of CRISPR/Cas9 technology and high-throughput screening, this study identified essential MYC-regulated genes involved in pathways associated with cancer development. This research provides a novel approach to explore MYC-dependent vulnerabilities in cancer cells, which is of significant importance.

MOLECULAR ONCOLOGY (2023)

Article Oncology

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

Johanna A. A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H. Tonino, Joost S. P. Vermaat, Martine E. D. Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J. Plattel, Mirian Brink, Marcel Nijland

Summary: This population-based study reveals the clinical characteristics associated with transformation and survival after transformation of marginal zone lymphoma (tMZL). Elevated LDH and nodal MZL subtype at MZL diagnosis increase the risk of transformation, while radiotherapy reduces the risk. Age >60 years and (immuno)chemotherapy before transformation are associated with an increased risk of relapse and mortality. Two-year progression-free survival and overall survival are higher for R-(mini)CHOP-treated tMZL patients.

BLOOD CANCER JOURNAL (2023)

No Data Available